Clinical trials: Degenerative Conditions, Neurologic
Arthritis, Degenerative
3VM for Treatment of Chronic Osteoarthritis Knee Pain
A double-blind, placebo-controlled, randomized dose ranging study for the use of 3VM1001 Cream, 2g three times daily, 3g three times daily, or 3g four times daily for treatment of chronic pain associated with osteoarthritis of…
- Trial name
- NCT03142178
- Testing
- Experimental: 3VM1001 active 2g Cream 3 times daily, Experimental: 3VM1001 active 3g Cream 3 times daily, Experimental: 3VM1001 active 3g Cream 4 times daily
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- CDA Research Group, Inc.
Alzheimer's Disease
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
To investigate the brain receptor occupancy of idalopirdine in patients with Alzheimer's disease (AD)
- Trial name
- NCT03307993
- Testing
- Idalopirdine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lundbeck A/S
Neurodegenerative Diseases
Continuation Study for Latozinemab
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
- Trial name
- NCT06111014
- Testing
- Latozinemab
- Where
- 18 sites in United States, Belgium and 8 more
- Volunteers
- 17 people
- Sponsor
- Alector Inc.
Parkinson's Disease
Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease
The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.
- Trial name
- NCT05894343
- Testing
- AAV-GAD
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- MeiraGTx, LLC
Alzheimer Disease
18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00103649
- Testing
- xaliproden (SR57746A)
- Where
- 121 sites in United States, Canada
- Volunteers
- 1,306 people
- Sponsor
- Sanofi
Alzheimer's Disease
Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease
This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).
- Trial name
- DISCOVER (NCT02925650)
- Testing
- Posiphen
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Annovis Bio Inc.
Huntington Disease
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their…
- Trial name
- NCT06667414
- Where
- 45 sites in United States, Argentina and 10 more
- Volunteers
- 574 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease
Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)
This study was designed to evaluate the pharmacokinetic profile, safety and efficacy in Parkinson's Disease patients.
- Trial name
- NCT00434304
- Testing
- Ropinirole prolonged release/extended release(PR/XR)
- Where
- 12 sites in Japan
- Volunteers
- 62 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease
Documentation of the effect of an direct or overlapping switch from another dopamine agonist to Sifrol® on motor function, psychopathological disturbances and mood, assessment of the reasons for the switch and the reasons for…
- Trial name
- NCT02231255
- Testing
- Sifrol®
- Volunteers
- 1,216 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)
This is a two part study to compare the PK of preladenant administered to participants with CRI to the PK of preladenant administered to healthy participants.
- Trial name
- NCT01323855
- Testing
- Preladenant
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease (PD), Deep Brain Stimulation
A Study of Buntanetap in Participants With PD
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts.
- Trial name
- NCT07284784
- Testing
- buntanetap/posiphen
- Where
- 29 sites in United States
- Volunteers
- 500 people
- Sponsor
- Annovis Bio Inc.
Amyotrophic Lateral Sclerosis
Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety, tolerability, and feasibility of Blood-Brain Barrier (BBB) opening using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent…
- Trial name
- NCT03321487
- Testing
- Blood-Brain Barrier opening with MRgFUS
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- InSightec
Parkinson's Syndrome
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
This is a phase 3, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian…
- Trial name
- NCT01950455
- Testing
- NAV5001
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Navidea Biopharmaceuticals
Alzheimer's Disease
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
The primary objective of the study was to examine the safety and tolerability of memantine in outpatients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT00857233
- Testing
- Memantine
- Where
- 33 sites in Canada
- Volunteers
- 297 people
- Sponsor
- H. Lundbeck A/S
Huntington's Disease
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920.
- Trial name
- NCT02342548
- Testing
- 20 mg BID of PF-02545920
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Amyotrophic Lateral Sclerosis
Three Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01, CNMAu8.EAP02, and CNMAu8.EAP06 for ALS
The primary objective of the intermediate expanded access protocol is to provide access to the investigational product, CNM-Au8, to up to 300 people living with ALS (pALS).
- Trial name
- NCT05281484
- Testing
- CNM-Au8
- Where
- 16 sites in United States
- Sponsor
- Clene Nanomedicine
Idiopathic Parkinson's Disease
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
- Trial name
- NCT00985517
- Testing
- CERE-120: Adeno-Associated Virus Delivery of Neurturin
- Where
- 11 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sangamo Therapeutics
Huntington Disease
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD).
- Trial name
- NCT03980938
- Testing
- neflamapimod
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- EIP Pharma Inc
Neurofibromatosis Type 1
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
This study in adolescent participants with NF1 who have inoperable PN is designed to evaluate the effect of a low fat meal on steady state selumetinib exposure; to assess the effect on GI tolerability when selumetinib is dosed…
- Trial name
- NCT05101148
- Testing
- Selumetinib
- Where
- 9 sites in United States, Poland and 2 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Essential Tremor, Parkinson's Disease
Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)
The primary objective of this study is to determine if the diagnostic performance of DaTscan™ single photon emission computed tomography (SPECT) imaging is different in non-Caucasian subjects compared with Caucasian subjects with…
- Trial name
- NCT01952678
- Testing
- DaTscan™ - Non-Caucasian Participants, DaTscan™ - Caucasian Participants
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- GE Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.